biostudies-literatureUnknown27(11)Alves Pinto IAstraZeneca do Brasil Ltda<h4>Background</h4>Targeted and immunotherapies are currently moving toward early-stage settings for patients with non-small cell lung cancer (NSCLC). Predictive biomarkers data are scarce in this scenario. We aimed to describe the frequency of EGFR mutations and PD-L1 expression levels in early-stage non-squamous patients with NSCLC from a large, single Brazilian oncology center.<h4>Methods</h4>We retrospectively evaluated patients with NSCLC diagnosed at an early-stage (IB to IIIA-AJCC seventh edition) at Barretos Cancer Hospital (n = 302). EGFR mutational status was assessed in FFPE tumor tissues using distinct methodologies (NGS, Cobas, or Sanger sequencing). PD-L1 expression was evaluated by immunohistochemistry (clone 22C3) and reported as Tumor Proportion Score (TPS), categorized asThe oncologiste899-e907https://www.ebi.ac.uk/biostudies/studies/S-EPMC9632322biostudies-literatureEGFR Mutations and PD-L1 Expression in Early-Stage Non-Small Cell Lung Cancer: A Real-World Data From a Single Center in Brazil.PMC9632322Oliveira da Silva MBiazotto Fernandes MFBerardinelli GNJacinto AAJunqueira Pinto GDde Oliveira Cavagna RVirginio da Silva ALNegreiros ISDuval da Silva VReis RMAlbino da Silva ECDias JMSantiago Goncalves MFLeal LFde Oliveira MAAlves Pinto IFerreira da Silva FASouza LCde Paula FECasagrande GMSSantana IVDe Marchi PfalseEGFR Mutations and PD-L1 Expression in Early-Stage Non-Small Cell Lung Cancer: A Real-World Data From a Single Center in Brazil.<h4>Background</h4>Targeted and immunotherapies are currently moving toward early-stage settings for patients with non-small cell lung cancer (NSCLC). Predictive biomarkers data are scarce in this scenario. We aimed to describe the frequency of EGFR mutations and PD-L1 expression levels in early-stage non-squamous patients with NSCLC from a large, single Brazilian oncology center.<h4>Methods</h4>We retrospectively evaluated patients with NSCLC diagnosed at an early-stage (IB to IIIA-AJCC seventh edition) at Barretos Cancer Hospital (n = 302). EGFR mutational status was assessed in FFPE tumor tissues using distinct methodologies (NGS, Cobas, or Sanger sequencing). PD-L1 expression was evaluated by immunohistochemistry (clone 22C3) and reported as Tumor Proportion Score (TPS), categorized as2022-01-01T00:00:00Z2022 Nov2026-07-14T16:04:14.094Z2024-11-08T20:16:10.234ZS-EPMC96323223609942110.1093/oncolo/oyac167